Malaria Vaccine at Scale: R21/Matrix-M & SII Supply
The R21/Matrix-M malaria vaccine—developed by the University of Oxford with Matrix-M adjuvant from Novavax and manufactured by the Serum Institute of India (SII)—was recommended by WHO in October 2023 and prequalified in December 2023, unlocking UN procurement and Gavi financing. By October 27, 2025, 24 African countries had introduced a malaria vaccine (RTS,S and/or R21)…